Michael Serzan, MD

Dr. Voss and Dr. Serzan close the discussion by reflecting on the evolution of treatment for advanced renal cell carcinoma (RCC) and the expanding therapeutic options now available to patients.

Dr. Voss and Dr. Serzan discuss emerging treatment options for patients with advanced clear cell renal cell carcinoma (RCC) following progression on prior immunotherapy.

Dr. Voss and Dr. Serzan discuss treatment options and sequencing after progression on first-line immunotherapy-based therapy in advanced renal cell carcinoma (RCC).

Dr. Voss and Dr. Serzan discuss treatment strategies in the post-immunotherapy setting for advanced clear cell renal cell carcinoma (RCC), focusing on whether immune checkpoint inhibition should be continued after progression.

Dr. Voss and Dr. Serzan focus on treatment considerations for patients with FH-deficient renal cell carcinoma (RCC), highlighting emerging evidence for distinct therapeutic approaches in this molecularly defined disease.

Dr. Voss and Dr. Serzan continue their discussion of treatment strategies for non-clear cell renal cell carcinoma (RCC), focusing on evidence for IO-TKI and IO-IO approaches across different histologic subtypes.

Dr. Voss and Dr. Serzan turn to non-clear cell renal cell carcinoma (RCC), highlighting the heterogeneity of these tumors and the ongoing unmet need for more effective treatment strategies.

Dr. Voss and Dr. Serzan discuss how disease burden and the location of metastases can influence first-line treatment selection in advanced renal cell carcinoma (RCC).

Dr. Voss and Dr. Serzan discuss factors that inform first-line treatment selection in advanced clear cell renal cell carcinoma (RCC) among established immune checkpoint inhibitor-based regimens.

Dr. Voss and Dr. Serzan discuss how the practical considerations surrounding cytoreductive nephrectomy can differ depending on the first-line regimen used in advanced renal cell carcinoma (RCC).

Dr. Serzan discusses the clinical significance of response depth in advanced renal cell carcinoma (RCC), highlighting evidence from the CLEAR trial that greater tumor reduction, particularly complete responses, is associated with more favorable long-term outcomes.

Dr. Voss and Dr. Serzan discuss the evolution of first-line treatment patterns in advanced renal cell carcinoma (RCC) over the past several years, highlighting the transition from tyrosine kinase inhibitor monotherapy toward immune-based combination regimens.

Dr. Martin Voss and Dr. Michael Serzan introduce the evolving treatment landscape for advanced renal cell carcinoma (RCC), emphasizing the importance of individualized first-line treatment selection.

Michael Serzan, MD, discusses the rationale for evaluating botensilimab/balstilimab for patients with advanced renal cell carcinoma.

Michael Serzan, MD, discusses the use of botensilimab/balstilimab in the treatment of patients with advanced renal cell carcinoma.